Warrants to Purchase 3,600,000 Shares of Common Stock AMERICAN RESOURCES CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • August 27th, 2019 • American Resources Corp • Services-miscellaneous repair services • New York
Contract Type FiledAugust 27th, 2019 Company Industry JurisdictionAmerican Resources Corporation, a Florida corporation (the “Company”), proposes, subject to the terms and conditions contained herein (this “Agreement”), to sell to you, Maxim Group LLC (“Maxim” or the “Underwriter”), an aggregate of 3,600,000 shares of the Company’s Class A common stock (the “Common Stock”), par value $0.0001 per share (the “Shares”) and warrants to purchase 3,600,000 shares of Common Stock (the “Warrants,” together with the Shares, the “Securities”). In addition, the Company proposes to grant to the Underwriter an option to purchase up to an additional 540,000 shares of Common Stock (the “Option Shares”) and/or Warrants to purchase up to an additional 540,000 shares of Common Stock (the “Option Warrants”) from the Company for the purpose of covering over-allotments, if any, in connection with the sale of the Securities (collectively, the “Option Securities”). The Securities and the Option Securities are collectively referred to herein as the context requires as the “
10,800,000 Shares of Common Stock and Warrants to Purchase 8,100,000 Shares of Common Stock TARONIS TECHNOLOGIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2019 • Taronis Technologies, Inc. • Special industry machinery, nec • New York
Contract Type FiledFebruary 8th, 2019 Company Industry JurisdictionTaronis Technologies, Inc. f/k/a MagneGas Applied Technology Solutions, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein (this “Agreement”), to sell to you, Maxim Group LLC (“Maxim” or the “Underwriter”), an aggregate of 10,800,000 shares of the Company’s common stock (the “Common Stock”), $0.001 par value per share (the “Shares”) and warrants to purchase 8,100,000 shares of Common Stock (the “Warrants,” together with the Shares, the “Securities”). In addition, the Company proposes to grant to the Underwriter an option to purchase up to an additional 1,120,000 shares of Common Stock (the “Option Shares”) and/or Warrants to purchase up to an additional 840,000 shares of Common Stock (the “Option Warrants”) from the Company for the purpose of covering over-allotments in connection with the sale of the Securities (collectively, the “Option Securities”). The Securities and the Option Securities are collectively referred to herein
Underwriting Agreement, dated October 4, 2013, by and among the Company, the Selling Stockholders, and the several underwriters named therein for whom Roth Capital Partners, LLC and Canaccord Genuity Inc. are acting as representativesUnderwriting Agreement • October 4th, 2013 • Lannett Co Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 4th, 2013 Company Industry JurisdictionThe Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the “Securities Act”), and the published rules and regulations thereunder (the “Rules”) adopted by the Securities and Exchange Commission (the “Commission”) a “shelf” registration statement on Form S-3 (No. 333-184721), which became effective as of December 7, 2012, including a base prospectus (the “Base Prospectus”) relating to common stock, debt securities and warrants of the Company that may be sold from time to time
Underwriting Agreement, dated December 14, 2010, by and among the Company, the Selling Stockholder, and Oppenheimer & Co. Inc. and Roth Capital Partners, LLC, as representatives of the several underwriters named thereinUnderwriting Agreement • December 16th, 2010 • Lannett Co Inc • Pharmaceutical preparations • New York
Contract Type FiledDecember 16th, 2010 Company Industry JurisdictionThe Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the “Securities Act”), and the published rules and regulations thereunder (the “Rules”) adopted by the Securities and Exchange Commission (the “Commission”) a “shelf” registration statement on Form S-3 (No. 333-162318), which became effective as of November 20, 2009, including a base prospectus (the “Base Prospectus”) relating to common stock, debt securities and warrants of the Company that may be sold from time to time by the Company or selling stockholders in accordance with Rule 415 of the Securities Act, and such amendments thereof as may have been required to the date of this Agreement. Copies of such Registration Statement (including all amendments thereof and all documents deemed incorporated by reference therein) and